 Brian Koss
| Title | Assistant Professor |
|---|
| Institution | University of Arkansas for Medical Sciences |
|---|
| Department | Biochemistry & Molecular Biology, College of Medicine |
|---|
| Address | 325 S. Elm St.
Mail Slot # 516
Little Rock AR 72205
|
|---|
| Phone | 501-686-5414 |
|---|
| vCard | Download vCard |
|---|
|
|
|
 Research 1R21CA292278-01 (TACKETT, ALAN J)Jun 1, 2024 - May 31, 2026 NIH/Nat. Cancer Institute
Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
Role: Principal Investigator |
| R21CA292278 (TACKETT, ALAN)Jun 1, 2024 - May 31, 2026 NIH
Leveraging cancer-evolved resistance mechanisms to enhance EZH2 activity in adoptive T cells
Role: Co-Principal Investigator |
| R21AI173759 (BURDINE, MARIE SCHLUTERMAN)Aug 5, 2023 - Jul 31, 2025 NIH
DNA-PKcs Regulation of LAT-Mediated Early TCR Signaling in CD4+ and CD8+ T Cells
Role: Co-Principal Investigator |
| DP5OD031863 (KOSS, BRIAN)Sep 14, 2021 - Aug 31, 2026 NIH
Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
Role: Principal Investigator |
| 1DP5OD031863 (KOSS, BRIAN)Sep 1, 2021 - Aug 31, 2026 NIH/Office of the Director
Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
Role: Principal Investigator |
| 1DP5OD031863-01 (KOSS, BRIAN)Sep 1, 2021 - Aug 31, 2026 NIH/Office of the Director
Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
Role: Principal Investigator |
| 5DP5OD031863 (KOSS, BRIAN)Sep 1, 2021 - Aug 31, 2026 NIH/Office of the Director
Discovering T cell proteome turnover dynamics to overcome the solid tumor microenvironment
Role: Principal Investigator |
| Early Termination 12/1/2020 (KOSS, BRIAN)Mar 1, 2019 - Feb 28, 2022 NIH/Nat. Cancer Institute
Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes
Role: Principal Investigator |
| F31CA232464 (KOSS, BRIAN)Mar 1, 2019 - Feb 28, 2022 NIH
Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes- Resubmission
Role: Principal Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Xia J, Zhao H, Edmondson JL, Koss B, Zhan F. Role of NEK2 in tumorigenesis and tumor progression. Trends Mol Med. 2024 Aug 23. PMID: 39181803.
-
Kelliher JL, Folkerts ML, Shen KV, Song W, Tengler K, Stiefel CM, Lee SO, Dray E, Zhao W, Koss B, Pannunzio NR, Leung JW. Evolved histone tail regulates 53BP1 recruitment at damaged chromatin. Nat Commun. 2024 May 31; 15(1):4634. PMID: 38821984.
-
Frett B, Stephens KE, Koss B, Melnyk S, Farrar J, Saha D, Roy Choudhury S. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia. Cancer Sci. 2024 Mar; 115(3):963-973. PMID: 38226414.
-
Morehead LC, Koss B, Fil D, Heflin B, Garg S, Wallis KF, Tackett AJ, Miousse IR. Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma. Mol Immunol. 2023 11; 163:188-195. PMID: 37837954.
-
Azevedo-Pouly AC, Appell LE, Burdine L, Rogers LJ, Morehead LC, Fil D, Barker M, Rainwater RR, Waldrip ZJ, Koss B, Burdine MS. Chemical inhibition of DNA-PKcs impairs the activation and cytotoxicity of CD4+ helper and CD8+ effector T cells. Immunol Cell Biol. 2023 08; 101(7):663-671. PMID: 37149747.
-
Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T Therapies in Solid Tumors: Opportunities and Challenges. Curr Oncol Rep. 2023 05; 25(5):479-489. PMID: 36853475.
-
Roy Choudhury S, Heflin B, Taylor E, Koss B, Avaritt NL, Tackett AJ. CRISPR/dCas9-KRAB-Mediated Suppression of S100b Restores p53-Mediated Apoptosis in Melanoma Cells. Cells. 2023 02 24; 12(5). PMID: 36899866.
-
Koss B, Shields BD, Taylor EM, Storey AJ, Byrum SD, Gies AJ, Washam CL, Choudhury SR, Hyun Ahn J, Uryu H, Williams JB, Krager KJ, Chiang TC, Mackintosh SG, Edmondson RD, Aykin-Burns N, Gajewski TF, Wang GG, Tackett AJ. Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719. PMID: 33004350.
-
Trentzsch M, Nyamugenda E, Miles TK, Griffin H, Russell S, Koss B, Cooney KA, Phelan KD, Tackett AJ, Iyer S, Boysen G, Baldini G. Delivery of phosphatidylethanolamine blunts stress in hepatoma cells exposed to elevated palmitate by targeting the endoplasmic reticulum. Cell Death Discov. 2020; 6:8. PMID: 32123584.
-
Taylor EM, Koss B, Davis LE, Tackett AJ. Histone Modifications as Biomarkers for Immunotherapy. Methods Mol Biol. 2020; 2055:213-228. PMID: 31502154.
-
Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, Wang GG. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019 10 03; 134(14):1176-1189. PMID: 31383640.
-
Chiang TC, Koss B, Su LJ, Washam CL, Byrum SD, Storey A, Tackett AJ. Effect of Sulforaphane and 5-Aza-2'-Deoxycytidine on Melanoma Cell Growth. Medicines (Basel). 2019 Jun 27; 6(3). PMID: 31252639.
-
Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. J Med Chem. 2019 04 25; 62(8):3971-3988. PMID: 30929420.
-
Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res. 2019 03 15; 79(6):1113-1123. PMID: 30674537.
-
Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ. Indicators of responsiveness to immune checkpoint inhibitors. Sci Rep. 2017 04 11; 7(1):807. PMID: 28400597.
-
Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017 Jan; 591(1):240-251. PMID: 27878989.
-
Koss B, Ryan J, Budhraja A, Szarama K, Yang X, Bathina M, Cardone MH, Nikolovska-Coleska Z, Letai A, Opferman JT. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines. Oncotarget. 2016 Mar 08; 7(10):11500-11. PMID: 26862853.
-
Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity. 2014 Dec 18; 41(6):947-59. PMID: 25500368.
-
Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT, Opferman JT. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood. 2013 Aug 29; 122(9):1587-98. PMID: 23881917.
-
Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013 Jun 15; 27(12):1351-64. PMID: 23788622.
-
Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol. 2012 Sep 21; 19(9):1175-86. PMID: 22999885.
-
Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, Youle RJ, Green DR, Opferman JT. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion?to respiration. Nat Cell Biol. 2012 Apr 29; 14(6):575-83. PMID: 22544066.
-
Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT. Ubiquitin-independent degradation of antiapoptotic MCL-1. Mol Cell Biol. 2010 Jun; 30(12):3099-110. PMID: 20385764.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2010 | 1 | | 2012 | 2 | | 2013 | 2 | | 2014 | 1 | | 2016 | 2 | | 2017 | 1 | | 2019 | 4 | | 2020 | 3 | | 2023 | 4 | | 2024 | 3 |
To return to the timeline, click here.
|
Koss's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|